Filed by Mylan N.V.
Pursuant to Rule 425 under
the Securities Act of 1933
and deemed filed pursuant to Rule 14a-6(b)
under the Securities Exchange Act of 1934
Subject Company: Mylan N.V.
Commission File No.: 333-199861
The following communication is being filed in connection with
the proposed business combination between Mylan N.V. and Upjohn
Inc., Pfizer Inc.’s off-patent branded and generic
established medicines business.
The following is the transcript of the Viatris brand reveal video
released on July 9, 2020 and made available for replay
beginning on July 9, 2020 on
In a world that is perpetually changing, there is increasing need
for steady leadership—companies demonstrating the courage to
address the world’s emerging healthcare challenges with passion and
VIATRIS is redefining the healthcare landscape—we are uniquely
positioned to be a source of stability with the commitment,
capability, and vision to meet the world’s evolving patient
VIATRIS believes in healthcare not as it is, but as it should
We know the way to provide access to a sustainable, affordable, and
diverse portfolio of high-quality medicines, regardless of a
patient’s geography or circumstance.
We are leading the way by providing a versatile, scalable platform
that combines best-in-class manufacturing and
supply capabilities with innovative solutions that span therapeutic
And as a partner of choice, we are pioneering a way to empower
companies of any size to leverage our distinctive Global Healthcare
Gateway, so products from across the industry and around the world
can rapidly and effectively reach patients where they live.
We do so with a collective spirit of resilience, driving forward
until each challenge is addressed and every opportunity
We are inspired by this moment of shared purpose—because as
VIATRIS, we know the way to empower people worldwide to live
healthier at every stage of life.
This communication contains “forward-looking statements”. Such
forward-looking statements may include, without limitation,
statements about the proposed combination of Upjohn Inc. (“Newco”)
and Mylan N.V. (“Mylan”), which will immediately follow the
proposed separation of the Upjohn business (the “Upjohn Business”)
from Pfizer Inc. (“Pfizer”) (the “proposed transaction”), the
expected timetable for completing the proposed transaction, the
benefits and synergies of the proposed transaction, future
opportunities for the combined company and products and any other
statements regarding Pfizer’s, Mylan’s, the Upjohn Business’s or
the combined company’s future operations, financial or operating
results, capital allocation, dividend